ABSTRACT
Introduction Temporomandibular disorder (TMD) is a common musculoskeletal pain condition with development of chronic symptoms in 49% of patients. Although a number of biological factors have shown an association with chronic TMD in cross-sectional and case control studies, there are currently no biomarkers that can predict the development of chronic symptoms. The PREDICT study aims to undertake analytical validation of a novel peak alpha frequency (PAF) and corticomotor excitability (CME) biomarker signature using a human model of the transition to sustained myofascial temporomandibular pain (masseter intramuscular injection of nerve growth factor [NGF]). This paper describes, a-priori, the methods and analysis plan.
Methods and analysis This study uses a multi-site longitudinal, experimental study to follow individuals for a period of 30 days as they progressively develop and experience complete resolution of NGF-induced muscle pain. 150 healthy participants will be recruited. Participants will complete twice daily electronic pain dairies from Day 0 to Day 30 and undergo assessment of pressure pain thresholds, and recording of PAF and CME on Days 0, 2 and 5. Intramuscular injection of NGF will be given into the right masseter muscle on Days 0 and 2. The primary outcome is pain sensitivity.
Ethics and dissemination Ethical approval has been obtained from The University of New South Wales (HC190206) and the University of Maryland Baltimore (HP-00085371). Dissemination will occur through presentations at National and International conferences and publications in international peer-reviewed journals.
Registration details ClinicalTrials.gov: NCT04241562 (prospective)
STRENGTHS AND LIMITATIONS OF THIS STUDY
PREDICT is the first study to undertake analytical validation of a peak alpha frequency and corticomotor excitability biomarker signature. The study will determine the sensitivity, specificity and accuracy of this biomarker signature at predicting pain sensitivity.
PREDICT will establish the reportable range of test results and determine automation and simplification of methods for biomarker detection in the clinic.
The methods and statistical analysis plan are pre-specified to ensure reporting transparency.
Future patient studies will be required for clinical validation.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04241562
Funding Statement
This project is funded by grant 1R61NS113269-01 from The National Institutes of Health to DAS, SMS and SC. SMS receives salary support from The National Health and Medical Research Council of Australia (1105040). SKM and KB hold University of New South Wales International Postgraduate Scholarships.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
De-identified, individual participant data will be made available immediately following publication via an open-access data repository.
